Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACR246
- Development stage
- Phase 1
- Lead developer
- Hangzhou Adcoris Biopharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ACR246 is an investigational antibody-drug conjugate (ADC) developed by Hangzhou Adcoris Biopharmacy. It targets the 5T4 transmembrane glycoprotein, which is overexpressed in a variety of solid tumors and associated with increased tumor invasiveness. The ADC consists of a humanized monoclonal antibody directed against 5T4, site-specifically conjugated to D2102, a novel DNA topoisomerase I inhibitor payload, via a stable and tumor microenvironment-cleavable linker. Upon binding to 5T4-positive tumor cells, ACR246 is internalized and releases D2102 intracellularly, inducing DNA damage, cell cycle arrest, and apoptosis specifically in cancer cells. Preclinical studies have demonstrated robust anti-tumor activity across multiple solid tumor models with favorable safety profiles. ACR246 is currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors[1][2][3][4][5].
- Other names
- anti-5t4/d-2102 antibody-drug conjugate
02
Targets
TPBG (Trophoblast glycoprotein)
Beyond the preview
Go deeper on ACR246.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACR246.